Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 4/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | PITRM1 | Q5JRX3 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209352 | 1.00 | ARG1 (0.47) | ARG1DPP4PITRM1DPP9FAP | |
| SCHEMBL17964184 | 0.88 | ARG1 (0.41) | ARG1DPP4PITRM1DPP9FAP | |
| SCHEMBL31323449 | 0.88 | ARG1 (0.41) | ARG1DPP4PITRM1DPP9FAP | |
| SCHEMBL23536 | 0.80 | ARG1 (0.49) | ARG1DPP4PITRM1DPP9FAP | |
| SCHEMBL23535 | 0.80 | ARG1 (0.49) | ARG1DPP4PITRM1DPP9FAP | |
| Hydrochloric Acid SCHEMBL905290 | 0.78 | ARG1 (0.47) | ARG1DPP4PITRM1DPP9FAP | |
| Hydrochloric Acid SCHEMBL905291 | 0.78 | ARG1 (0.47) | ARG1DPP4PITRM1DPP9FAP | |
| Hydrochloric Acid SCHEMBL16393846 | 0.78 | ARG1 (0.47) | ARG1DPP4PITRM1DPP9FAP | |
| SCHEMBL31498016 | 0.77 | ARG1 (0.42) | ARG1SLC1A2 | |
| SCHEMBL17031903 | 0.73 | ARG1 (0.42) | ARG1SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002396-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2023081764-A1 | HEXADEPSIPEPTIDE COMPOUNDS AND METHODS OF USING THE SAME | ZYMERGEN INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022076563-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-8076287-B2 | Cyclic hexadepsipeptides, processes for their production and their use as pharmaceuticals | THALLION PHARMACEUTICALS INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| US-20090215789-A1 | CYCLIC HEXADEPSIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | THALLION PHARMACEUTICALS, INC. (CA) | 2009-08-27 | — | — | US | disclosed |
| WO-2007126849-A1 | CYCLIC HEXADEPSIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | THALLION PHARMACEUTICALS INC. (CA) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002396-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | MKI67, CCNC, PCNA | ARG1 1651/4885DPP4 1925/4885PITRM1 1132/4885 |
| US-20090215789-A1 | CYCLIC HEXADEPSIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | HM13, VIP, NPEPPS | ARG1 3383/4885DPP4 50/4885PITRM1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.